Noritaka Ushio
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Noritaka Ushio has a total of 60 co-authors. Here are the top co-authors by number of shared publications:
- Kazuma Yamakawa
Department of Emergency and Critical Care Medicine, Osaka Medical and Pharmaceutical University, Takatsuki, Osaka, Japan
3 shared publications Akira Takasu
Department of Emergency and Critical Care Medicine Osaka Medical and Pharmaceutical University Takatsuki Japan
2 shared publications- Ryo Hisamune
Department of Emergency and Critical Care Medicine, Osaka Medical and Pharmaceutical University, Takatsuki, Japan
2 shared publications - Ryo Yamamoto
Department of Emergency and Critical Care Medicine, Keio University School of Medicine, Tokyo, Japan
2 shared publications Akihito Tampo
Department of Emergency Medicine, Asahikawa City Hospital, Asahikawa, Hokkaido, Japan
1 shared publicationAkira Endo
Department of Acute Critical Care Medicine, Tsuchiura Kyodo General Hospital, Tsuchiura, Ibaraki, Japan
1 shared publication
Latest Publications
- Open Access
- 1 January 2026
- Published by Wiley in Acute Medicine & Surgery
- Vol. 13 (1)
Myeloid‐Derived Suppressor Cell Trajectories in Relation to 90‐Day Functional Status and PIICS After Sepsis: A Pilot Study
Introduction: Improved survival from sepsis has shifted attention to poor long‐term outcomes among survivors. Although myeloid‐derived suppressor cells (MDSCs) are associated with short‐term mortality in sepsis, their role in long‐term outcomes, including post‐intensive care syndrome (PICS) and persistent inflammation, immunosuppression, and catabolism syndrome, remains unclear. Methods: We enrolled adult patients with sepsis admitted to the intensive care unit (ICU) and healthy controls to examine immunological profiles in relation to long‐term outcomes. MDSC frequency/phenotype and key cytokines were assessed from serial blood samples collected through Day 90 after ICU admission, using a standardized flow cytometry protocol and immunoassays, respectively. Clinical and demographic variables were retrieved from medical records. For analyses, we stratified patients by the 90‐day Barthel Index after ICU admission (≥ 70 vs. < 70), reflecting dependence in activities of daily living (ADL), a core component of physical PICS. Results: This study included 14 patients with sepsis and 9 healthy volunteers. Across days 1–90, M‐MDSC percentages remained higher in the poor ADL group (Barthel Index < 70) than in the good ADL group (Barthel Index ≥ 70), whereas PMN‐MDSCs showed no clear between‐group difference. CD86 on M‐MDSCs showed time‐dependent divergence between groups, whereas cytokines mainly varied over time without consistent group differences. Conclusions: Sustained elevation of M‐MDSCs, together with time‐varying differences in CD86 expression on M‐MDSCs, appeared to be associated with poorer physical function after sepsis, suggesting that persistent immune dysregulation may contribute to functional impairment. Clinical Trial: The study protocol was registered in the University Hospital Medical Information Network Clinical Trials Registry (UMIN‐CTR, Registration No. UMIN000041512; registration date: August 21, 2020).
- 1 January 2026
- Published by Wiley in Acute Medicine & Surgery
- Vol. 13 (1)
Open AccessMyeloid‐Derived Suppressor Cell Trajectories in Relation to 90‐Day Functional Status and PIICS After Sepsis: A Pilot Study
Introduction: Improved survival from sepsis has shifted attention to poor long‐term outcomes among survivors. Although myeloid‐derived suppressor cells (MDSCs) are associated with short‐term mortality in sepsis, their role in long‐term outcomes, including post‐intensive care syndrome (PICS) and persistent inflammation, immunosuppression, and catabolism syndrome, remains unclear. Methods: We enrolled adult patients with sepsis admitted to the intensive care unit (ICU) and healthy controls to examine immunological profiles in relation to long‐term outcomes. MDSC frequency/phenotype and key cytokines were assessed from serial blood samples collected through Day 90 after ICU admission, using a standardized flow cytometry protocol and immunoassays, respectively. Clinical and demographic variables were retrieved from medical records. For analyses, we stratified patients by the 90‐day Barthel Index after ICU admission (≥ 70 vs. < 70), reflecting dependence in activities of daily living (ADL), a core component of physical PICS. Results: This study included 14 patients with sepsis and 9 healthy volunteers. Across days 1–90, M‐MDSC percentages remained higher in the poor ADL group (Barthel Index < 70) than in the good ADL group (Barthel Index ≥ 70), whereas PMN‐MDSCs showed no clear between‐group difference. CD86 on M‐MDSCs showed time‐dependent divergence between groups, whereas cytokines mainly varied over time without consistent group differences. Conclusions: Sustained elevation of M‐MDSCs, together with time‐varying differences in CD86 expression on M‐MDSCs, appeared to be associated with poorer physical function after sepsis, suggesting that persistent immune dysregulation may contribute to functional impairment. Clinical Trial: The study protocol was registered in the University Hospital Medical Information Network Clinical Trials Registry (UMIN‐CTR, Registration No. UMIN000041512; registration date: August 21, 2020).
- Open Access
- 1 January 2026
- Published by Wiley in Acute Medicine & Surgery
- Vol. 13 (1) , e70145
Outcomes and Risk Factors for In‐Hospital Mortality in Mild‐to‐Moderate Trauma Patients: A Nationwide Observational Study
Background: Although minor (mild‐to‐moderate) trauma generally leads to favorable outcomes, some patients experience in‐hospital mortality. Traditional trauma severity scores alone may not sufficiently reflect the prognostic variability in aging populations with comorbidities. This study examined the associations between patient characteristics and in‐hospital mortality among patients with minor trauma. Methods: This retrospective cohort study used data from adult patients with minor trauma, defined by an Injury Severity Score (ISS) < 16 from the Japan Trauma Data Bank. A logistic regression analysis was performed to evaluate associations between mortality and patient characteristics, including age, sex, ISS, and the Charlson Comorbidity Index (CCI) score. Subgroup analyses were conducted among patients with moderate trauma (ISS 9–15) to examine the associations between the Abbreviated Injury Scale (AIS) scores of injuries at three specific anatomical regions and in‐hospital mortality. Results: After applying the exclusion criteria, of the 56,821 patients with ISS < 16 identified in the Japan Trauma Data Bank, 50,087 were included in the final analysis. The logistic regression analysis identified older age, male sex, ISS ≥ 9, and higher CCI scores as independent predictors of in‐hospital mortality. In patients with moderate trauma, the AIS scores of injuries involving the three regions (head/neck, abdomen, and external/other trauma injury regions) were significantly associated with increased mortality. Conclusion: Among patients with minor trauma, advanced age, male sex, comorbidities, and specific injury regions were associated with increased in‐hospital mortality. These findings highlight the importance of early risk recognition and tailored clinical management in this population.
- 1 January 2026
- Published by Wiley in Acute Medicine & Surgery
- Vol. 13 (1) , e70145
Open AccessOutcomes and Risk Factors for In‐Hospital Mortality in Mild‐to‐Moderate Trauma Patients: A Nationwide Observational Study
Background: Although minor (mild‐to‐moderate) trauma generally leads to favorable outcomes, some patients experience in‐hospital mortality. Traditional trauma severity scores alone may not sufficiently reflect the prognostic variability in aging populations with comorbidities. This study examined the associations between patient characteristics and in‐hospital mortality among patients with minor trauma. Methods: This retrospective cohort study used data from adult patients with minor trauma, defined by an Injury Severity Score (ISS) < 16 from the Japan Trauma Data Bank. A logistic regression analysis was performed to evaluate associations between mortality and patient characteristics, including age, sex, ISS, and the Charlson Comorbidity Index (CCI) score. Subgroup analyses were conducted among patients with moderate trauma (ISS 9–15) to examine the associations between the Abbreviated Injury Scale (AIS) scores of injuries at three specific anatomical regions and in‐hospital mortality. Results: After applying the exclusion criteria, of the 56,821 patients with ISS < 16 identified in the Japan Trauma Data Bank, 50,087 were included in the final analysis. The logistic regression analysis identified older age, male sex, ISS ≥ 9, and higher CCI scores as independent predictors of in‐hospital mortality. In patients with moderate trauma, the AIS scores of injuries involving the three regions (head/neck, abdomen, and external/other trauma injury regions) were significantly associated with increased mortality. Conclusion: Among patients with minor trauma, advanced age, male sex, comorbidities, and specific injury regions were associated with increased in‐hospital mortality. These findings highlight the importance of early risk recognition and tailored clinical management in this population.
- Open Access
Early restricted oxygen therapy after resuscitation from cardiac arrest (ER-OXYTRAC): protocol for a stepped-wedge cluster randomised controlled trial
Introduction: Cardiac arrest is a critical condition, and patients often experience postcardiac arrest syndrome (PCAS) even after the return of spontaneous circulation (ROSC). Administering a restricted amount of oxygen in the early phase after ROSC has been suggested as a potential therapy for PCAS; however, the optimal target for arterial partial pressure of oxygen or peripheral oxygen saturation (SpO2) to safely and effectively reduce oxygen remains unclear. Therefore, we aimed to validate the efficacy of restricted oxygen treatment with 94%–95% of the target SpO2 during the initial 12 hours after ROSC for patients with PCAS. Methods and analysis: ER-OXYTRAC (early restricted oxygen therapy after resuscitation from cardiac arrest) is a nationwide, multicentre, pragmatic, single-blind, stepped-wedge cluster randomised controlled trial targeting cases of non-traumatic cardiac arrest. This study includes adult patients with out-of-hospital or in-hospital cardiac arrest who achieved ROSC in 39 tertiary centres across Japan, with a target sample size of 1000. Patients whose circulation has returned before hospital arrival and those with cardiac arrest due to intracranial disease or intoxication are excluded. Study participants are assigned to either the restricted oxygen (titration of a fraction of inspired oxygen with 94%–95% of the target SpO2) or the control (98%–100% of the target SpO2) group based on cluster randomisation per institution. The trial intervention continues until 12 hours after ROSC. Other treatments for PCAS, including oxygen administration later than 12 hours, can be determined by the treating physicians. The primary outcome is favourable neurological function, defined as cerebral performance category 1–2 at 90 days after ROSC, to be compared using an intention-to-treat analysis. Ethics and dissemination: This study has been approved by the Institutional Review Board at Keio University School of Medicine (approval number: 20211106). Written informed consent will be obtained from all participants or their legal representatives. Results will be disseminated via publications and presentations. Trial registration number: UMIN Clinical Trials Registry (UMIN000046914).
Open AccessEarly restricted oxygen therapy after resuscitation from cardiac arrest (ER-OXYTRAC): protocol for a stepped-wedge cluster randomised controlled trial
Introduction: Cardiac arrest is a critical condition, and patients often experience postcardiac arrest syndrome (PCAS) even after the return of spontaneous circulation (ROSC). Administering a restricted amount of oxygen in the early phase after ROSC has been suggested as a potential therapy for PCAS; however, the optimal target for arterial partial pressure of oxygen or peripheral oxygen saturation (SpO2) to safely and effectively reduce oxygen remains unclear. Therefore, we aimed to validate the efficacy of restricted oxygen treatment with 94%–95% of the target SpO2 during the initial 12 hours after ROSC for patients with PCAS. Methods and analysis: ER-OXYTRAC (early restricted oxygen therapy after resuscitation from cardiac arrest) is a nationwide, multicentre, pragmatic, single-blind, stepped-wedge cluster randomised controlled trial targeting cases of non-traumatic cardiac arrest. This study includes adult patients with out-of-hospital or in-hospital cardiac arrest who achieved ROSC in 39 tertiary centres across Japan, with a target sample size of 1000. Patients whose circulation has returned before hospital arrival and those with cardiac arrest due to intracranial disease or intoxication are excluded. Study participants are assigned to either the restricted oxygen (titration of a fraction of inspired oxygen with 94%–95% of the target SpO2) or the control (98%–100% of the target SpO2) group based on cluster randomisation per institution. The trial intervention continues until 12 hours after ROSC. Other treatments for PCAS, including oxygen administration later than 12 hours, can be determined by the treating physicians. The primary outcome is favourable neurological function, defined as cerebral performance category 1–2 at 90 days after ROSC, to be compared using an intention-to-treat analysis. Ethics and dissemination: This study has been approved by the Institutional Review Board at Keio University School of Medicine (approval number: 20211106). Written informed consent will be obtained from all participants or their legal representatives. Results will be disseminated via publications and presentations. Trial registration number: UMIN Clinical Trials Registry (UMIN000046914).
- Open Access
- 12 January 2023
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 18 (1) , e0267339
Effect of a systematic lung-protective protocol for COVID-19 pneumonia requiring invasive ventilation: A single center retrospective study
The benefits of introducing a systematic lung-protective protocol for coronavirus disease 2019 (COVID-19) pneumonia requiring invasive ventilation in the intensive care unit (ICU) are unknown. Herein, we aimed to evaluate the clinical effects of introducing such a protocol in terms of mortality, duration of ventilation, and length of ICU stay. In this single-centre, retrospective, quality comparison study, we identified patients with COVID-19 pneumonia who received invasive ventilation in our ICU between February 2020 and October 2021. We established a systematic lung-protective protocol for the pre-introduction group until March 2021 and the post-introduction group after April 2021. Patients who did not receive invasive ventilation and who underwent veno-venous extracorporeal membrane oxygenation in a referring hospital were excluded. We collected patient characteristics at the time of ICU admission, including age, sex, body mass index (BMI), comorbidities, sequential organ failure assessment (SOFA) score, acute physiology and chronic health evaluation II (APACHE II) score, and Murray score. The study outcomes were ICU mortality, length of ICU stay, and duration of ventilation. The pre-introduction and post-introduction groups included 18 and 50 patients, respectively. No significant differences were observed in sex, BMI, SOFA score, APACHE II score, and Murray score; however, age was lower in the post-introduction group (70 vs. 56, P = 0.003). The introduction of this protocol did not improve ICU mortality. However, it reduced the ICU length of stay (26 days vs. 11 days, P = 0.003) and tended to shorten the duration of ventilation (15 days vs. 10 days, P = 0.06). The introduction of the protocol was associated with a decrease in the length of ICU stay and duration of ventilation; however, it did not change mortality. The application of the protocol could improve the security of medical resources during the COVID-19 pandemic. Further prospective multicentre studies are needed.
- 12 January 2023
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 18 (1) , e0267339
Open AccessEffect of a systematic lung-protective protocol for COVID-19 pneumonia requiring invasive ventilation: A single center retrospective study
The benefits of introducing a systematic lung-protective protocol for coronavirus disease 2019 (COVID-19) pneumonia requiring invasive ventilation in the intensive care unit (ICU) are unknown. Herein, we aimed to evaluate the clinical effects of introducing such a protocol in terms of mortality, duration of ventilation, and length of ICU stay. In this single-centre, retrospective, quality comparison study, we identified patients with COVID-19 pneumonia who received invasive ventilation in our ICU between February 2020 and October 2021. We established a systematic lung-protective protocol for the pre-introduction group until March 2021 and the post-introduction group after April 2021. Patients who did not receive invasive ventilation and who underwent veno-venous extracorporeal membrane oxygenation in a referring hospital were excluded. We collected patient characteristics at the time of ICU admission, including age, sex, body mass index (BMI), comorbidities, sequential organ failure assessment (SOFA) score, acute physiology and chronic health evaluation II (APACHE II) score, and Murray score. The study outcomes were ICU mortality, length of ICU stay, and duration of ventilation. The pre-introduction and post-introduction groups included 18 and 50 patients, respectively. No significant differences were observed in sex, BMI, SOFA score, APACHE II score, and Murray score; however, age was lower in the post-introduction group (70 vs. 56, P = 0.003). The introduction of this protocol did not improve ICU mortality. However, it reduced the ICU length of stay (26 days vs. 11 days, P = 0.003) and tended to shorten the duration of ventilation (15 days vs. 10 days, P = 0.06). The introduction of the protocol was associated with a decrease in the length of ICU stay and duration of ventilation; however, it did not change mortality. The application of the protocol could improve the security of medical resources during the COVID-19 pandemic. Further prospective multicentre studies are needed.